OncoCyte Corporation (NASDAQ: OCX) reported Q3 EPS of ($0.81), $0.32 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $430 thousand versus the consensus estimate of $437.5 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.